(Q51563502)

English

Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis.

scientific article published in October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

type 2 diabetes

0 references

circulatory system

1 reference

based on heuristic

inferred from title

author name string

B R Peskin

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

A V Shcheprov

2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

K S Boye

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

S Bruce

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

D G Maggs

5

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

J A Gaebler

6

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

publication date

1 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

13

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

10

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

921-927

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Total cardiovascular risk management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Archimedes: a trial-validated model of diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Validation of the Archimedes Diabetes Model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01430.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01430.X

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/21624032

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51563502&oldid=1242801128"